Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series
Goodman R, Jung S, Quintos J, Johnson D. Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series. The Oncologist 2023, 28: e839-e842. PMID: 37338166, PMCID: PMC10485291, DOI: 10.1093/oncolo/oyad184.Peer-Reviewed Original ResearchConceptsMetastatic melanomaCase seriesCombination of anti-PD-1Multiple lines of systemic therapyCombined immune checkpoint inhibitorsLines of systemic therapyRefractory to standard treatmentTemozolomide combination therapyAnti-PD-1Immune checkpoint inhibitorsMetastatic melanoma patientsResponse to nivolumabCombination nivolumabLocal/regional therapyCheckpoint inhibitorsSalvage therapyTumor remissionMelanoma patientsSystemic therapyCombination therapySymptomatic improvementTargeted therapyChemotherapy agentsStandard treatmentTemozolomide
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply